- Stocks
- Pharma & Healthcare
- Brooks Laboratories
Brooks Laboratories share price
NSE: BROOKSPharma & HealthcareDrug Manufacturers - Specialty & Generic
Brooks Laboratories at a glance
Brooks Laboratories (NSE: BROOKS) closed at ₹63.12 on 22 Oct 2026, up 4.31% on the day. With a market capitalisation of ₹186 Cr, it ranks 2312th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 7.6× trailing earnings, against a return on equity of −10.2% in FY25. Over the past year the share price has fallen 49.8%. Its 52-week range is ₹36.30 (30 Mar 2026) to ₹123.54 (23 Oct 2025); the last close is 48.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹20 Cr (−13.3% year on year) and net profit ₹1 Cr (−54.5%), on a consolidated basis. Promoters held 52.62% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹186 CrRank 2312 on NSE
- P/E (trailing)
- 7.6×
- Price to book
- 3.24×FY25
- EPS (TTM)
- ₹8.35to Q4 FY26
- ROE
- −10.2%FY25
- ROCE
- 4.2%FY25
- Debt to equity
- 0.06FY25
- Net profit margin
- 3.7%FY25
- Book value / share
- ₹33.30FY25
- 52-week high
- ₹123.5423 Oct 2025
- 52-week low
- ₹36.3030 Mar 2026
- 1-year return
- −49.8%
- RSI (14-day)
- 50
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +4.31% | −7.9% | +6.8% | −5.9% | −49.8% |
Brooks Laboratories quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹18 Cr | ₹21 Cr | ₹38 Cr | ₹23 Cr | ₹26 Cr | ₹23 Cr | ₹17 Cr | ₹20 Cr |
| Revenue YoY | +14.2% | −14.5% | +76.8% | +31.6% | +42.3% | +12.8% | −56.9% | −13.3% |
| Net profit | −₹0 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹2 Cr | ₹0 Cr | ₹1 Cr |
| Net profit YoY | — | −18.6% | +20.7% | +346.7% | — | +133.3% | −57.1% | −54.5% |
| Net margin | −1.2% | 4.6% | 1.8% | 5.7% | 10.4% | 9.6% | 1.8% | 3.0% |
| EPS | −₹0.94 | −₹1.51 | −₹1.75 | −₹0.54 | ₹3.25 | ₹2.71 | ₹1.87 | ₹0.52 |
Brooks Laboratories financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | ₹77 Cr | ₹91 Cr | ₹63 Cr | ₹79 Cr | ₹83 Cr |
| Operating profit | −₹9 Cr | −₹24 Cr | −₹35 Cr | ₹2 Cr | ₹3 Cr |
| Net profit | −₹19 Cr | −₹19 Cr | −₹28 Cr | ₹2 Cr | ₹3 Cr |
| EPS (₹) | −₹8.00 | −₹8.00 | −₹13.00 | −₹8.00 | −₹4.00 |
| Cash from operations | ₹4 Cr | −₹37 Cr | −₹14 Cr | −₹10 Cr | ₹3 Cr |
| Total debt | ₹14 Cr | ₹9 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹79 Cr | ₹63 Cr | ₹74 Cr | ₹66 Cr | ₹98 Cr |
Brooks Laboratories shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% |
| Foreign institutions | 0.05% | 0.00% | 0.01% | 0.09% | 0.17% | 0.00% |
| Domestic institutions | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% | 10.38% |
| Non-institutions | 36.95% | 37.00% | 37.00% | 36.91% | 36.84% | 37.00% |
Brooks Laboratories vs peers
The listed Pharma & Healthcare companies nearest to Brooks Laboratories by market capitalisation.
Ask anything about Brooks Laboratories
Pivot answers on the live chart with evidence you can check, and tests strategies against BROOKS's own history. Try: “Why has BROOKS moved over the last three months?” · “Backtest a 50-day moving-average crossover on BROOKS over five years” · “Compare BROOKS with CORALAB on margins and valuation”
Frequently asked questions about Brooks Laboratories
What is the share price of Brooks Laboratories today?
Brooks Laboratories (NSE: BROOKS) last closed at ₹63.12 on 22 Oct 2026. Its 52-week high is ₹123.54 and its 52-week low is ₹36.30.
What is the market cap of Brooks Laboratories?
Brooks Laboratories' market capitalisation is ₹186 Cr (₹186 Cr) at the 22 Oct 2026 close, ranking 2312th among the NSE companies Pivot tracks.
What is the P/E ratio of Brooks Laboratories?
Brooks Laboratories trades at a trailing P/E of 7.6.
What is the ROE and ROCE of Brooks Laboratories?
Return on equity was −10.2% in FY25 and return on capital employed was 4.2% in FY25 (consolidated figures).
Is Brooks Laboratories a debt-free company?
No. Brooks Laboratories' debt-to-equity ratio was 0.06 in FY25, with total debt of ₹0 Cr.
What were Brooks Laboratories' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Brooks Laboratories reported revenue of ₹20 Cr, −13.3% year on year, and net profit of ₹1 Cr, −54.5% year on year.
How has Brooks Laboratories stock performed over the last year?
Brooks Laboratories' share price has fallen 49.8% over the past year, −5.9% over three months and +6.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Brooks Laboratories?
As of 30 Jun 2026: promoters 52.62%, foreign institutions 0.00%, domestic institutions 10.38%, non-institutions 37.00%.
Who are Brooks Laboratories' competitors?
The listed Pharma & Healthcare companies closest to Brooks Laboratories by market cap are Coral Labs, Aashka Hospital, OXYGENTA PHARMA, Accretion Nutra, Earkart and Novelix Pharma.
Is Brooks Laboratories a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Brooks Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BROOKS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text